- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | ||
| Fr | UniQure falls further on Makary comments | ||
| Fr | Moderna's combination flu, COVID shot wins over European drug regulators | ||
| Fr | Generate caps a strong month for biotech IPOs with $400M offering | ||
| Do | Lilly's GLP-1 pill tops Novo's Rybelsus in head-to-head trial | ||
| Do | Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer | ||
| Do | Sarepta CEO Doug Ingram to retire, with company at a crossroads | ||
| Mi | Trump's State of the Union trumpets healthcare greatest hits, but no new policies | ||
| Mi | Alkermes' Richard Pops to step down after three-decade run as CEO | ||
| Mi | GSK to acquire 35Pharma in $950M deal for cardiovascular drug | ||
| Mi | 15 States sue HHS over changes to childhood vaccine schedule | ||
| Mi | With Vivtex deal, Novo gains a chance at better oral obesity drugs | ||
| Mi | BreezeBio banks $60M to make more precise genetic medicines | ||
| Di | Vir climbs on Astellas deal, study results for 'masked' T cell engager | ||
| Di | Novo to cut GLP-1 drug prices; Palvella soars on study data | ||
| Di | Novo, searching for a spark, spotlights new data for three-pronged obesity drug | ||
| Di | Slate starts up with $130M and a headache drug from China | ||
| Mo | FDA fleshes out new roadmap for testing personalized therapies | ||
| Mo | Novo's next-gen obesity shot fails to match Lilly drug in head-to-head study | ||
| Mo | Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy | ||
| Mo | Merck to split cancer, specialty drug businesses in leadership shakeup | ||
| Mo | All about cell therapy process characterization | ||
| Mo | Small and mighty: single-domain antibodies pack a biological punch | ||
| 20.02. | Grail's multi-cancer early detection test misses study goal | ||
| 20.02. | Supreme Court invalidates Trump tariffs based on emergency powers |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.